-
New data shows the pandemic exacerbated an already fast-growing problem, tipping more Americans' weight over the scales into unhealthy territory.
-
Clinical trials show Wegovy triples the average weight loss seen with other drugs. Whether it will reach many patients largely depends on whether insurers decide to cover it.
-
A newly-approved drug, Wegovy, has shown to have significant weight loss benefits. But it's unclear if insurers will cover the cost of the medication for the millions of Americans who might need it.
-
In company-funded studies, participants taking the Novo Nordisk drug Wegovy had average weight loss of about 34 pounds. In a comparison group getting dummy shots, the average loss was under 6 pounds.
-
In the U.S. South — home to nine of the nation's 12 heaviest states — obesity is playing a role not only in COVID-19 outcomes but in the calculus of the vaccination rollout.
-
As cities offer vaccine appointments for people with a BMI of at least 30 — the medical benchmark for obesity — Dr. Fatima Stanford pushes back against the shame faced by those with the disease.
-
Governor Kevin Stitt gave his third State of the State Address on Monday before a joint session of the State House and Senate for the 58th Oklahoma…
-
Data shows people with certain chronic conditions are more likely to get severe COVID-19 symptoms. Why are they hit harder and what explains the disease's disproportionate affect on African Americans?
-
Over 11% of U.S. households worry about running out of food and rationing what they have. Meanwhile, 2 in 5 adults are obese. Research suggests the links between the two are stronger than we think.
-
A comprehensive new report from UNICEF calls attention to the surge in obesity in developing countries — even as they're dealing with children who are undernourished.